BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 6% – What’s Next?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s stock price rose 6% during mid-day trading on Tuesday . The stock traded as high as $10.59 and last traded at $10.4350. 1,106,497 shares changed hands during mid-day trading, a decline of 78% from the average session volume of 4,964,359 shares. The stock had previously closed at $9.84.

Wall Street Analyst Weigh In

BCRX has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, June 30th. Royal Bank Of Canada cut their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Citizens Jmp lifted their target price on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Thursday, May 7th. Needham & Company LLC decreased their target price on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Finally, JPMorgan Chase & Co. started coverage on shares of BioCryst Pharmaceuticals in a research note on Monday, July 13th. They issued a “neutral” rating and a $12.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $20.60.

BioCryst Pharmaceuticals Stock Up 7.2%

The company has a market cap of $2.68 billion, a price-to-earnings ratio of -7.03 and a beta of 0.55. The stock’s 50-day simple moving average is $9.36 and its 200 day simple moving average is $8.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The business had revenue of $218.25 million during the quarter, compared to analysts’ expectations of $183.28 million. During the same period last year, the business earned $0.15 earnings per share. The business’s revenue for the quarter was up 33.6% on a year-over-year basis. On average, sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.44 EPS for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Larson Financial Group LLC boosted its position in shares of BioCryst Pharmaceuticals by 1,188.0% during the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after buying an additional 3,267 shares during the period. Focus Partners Wealth acquired a new position in BioCryst Pharmaceuticals during the 3rd quarter worth about $77,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in BioCryst Pharmaceuticals by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 2,115 shares in the last quarter. Envestnet Portfolio Solutions Inc. purchased a new position in BioCryst Pharmaceuticals during the 4th quarter valued at about $81,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in BioCryst Pharmaceuticals in the 3rd quarter valued at about $81,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.